NASDAQ:CERS - Cerus Stock Price, Price Target & More

Get Started

$6.49 -0.10 (-1.52 %)

(As of 05/27/2018 04:00 PM ET)

Previous Close$6.49

Today's Range$6.43 - $6.6390

52-Week Range$1.93 - $6.79

Volume486,976 shs

Average Volume1.06 million shs

Market Capitalization$847.23 million

P/E RatioN/A

Dividend YieldN/A

Beta1.72

About Cerus (NASDAQ:CERS)

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. The company's INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion. It markets platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was founded in 1991 and is headquartered in Concord, California.

Receive CERS News and Ratings via Email

Sign-up to receive the latest news and ratings for CERS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Supplies

SectorMedical

SymbolNASDAQ:CERS

CUSIP15708510

Webwww.cerus.com

Phone925-288-6000

Debt

Debt-to-Equity Ratio0.33

Current Ratio5.66

Quick Ratio5.10

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$43.57 million

Price / Sales19.44

Cash FlowN/A

Price / CashN/A

Book Value$0.66 per share

Price / Book9.83

Profitability

EPS (Most Recent Fiscal Year)($0.56)

Net Income$-60,580,000.00

Net Margins-111.46%

Return on Equity-111.19%

Return on Assets-52.81%

Miscellaneous

Employees215

Outstanding Shares130,540,000

Cerus (NASDAQ:CERS) Frequently Asked Questions

What is Cerus' stock symbol?

Cerus trades on the NASDAQ under the ticker symbol "CERS."

How were Cerus' earnings last quarter?

Cerus Co. (NASDAQ:CERS) posted its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.12) by $0.01. The biotechnology company earned $13.56 million during the quarter, compared to analysts' expectations of $12.22 million. Cerus had a negative return on equity of 111.19% and a negative net margin of 111.46%. The business's quarterly revenue was up 93.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.18) EPS. View Cerus' Earnings History.

When is Cerus' next earnings date?

Cerus is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Cerus.

What price target have analysts set for CERS?

4 brokerages have issued twelve-month price targets for Cerus' stock. Their forecasts range from $5.00 to $6.00. On average, they expect Cerus' share price to reach $5.25 in the next year. View Analyst Ratings for Cerus.

What are Wall Street analysts saying about Cerus stock?

Here are some recent quotes from research analysts about Cerus stock:

1. According to Zacks Investment Research, "Cerus Corporation is developing medical products based on a platform technology that prevents nucleic acid replication. The company's initial application of this technology is the development of systems to inactivate viruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation. " (5/24/2018)
2. Cantor Fitzgerald analysts commented, "This afternoon, CERS announced that its Ph 3 transfusion study (SPARC) evaluating its INTERCEPT-treated red blood cells in thalassemia (chronic anemia) patients achieved its primary efficacy and safety endpoints." (1/23/2018)

Who are some of Cerus' key competitors?

Some companies that are related to Cerus include NovoCure (NVCR), Merit Medical Systems (MMSI), NuVasive (NUVA), Nevro (NVRO), iRhythm (IRTC), Mazor Robotics (MZOR), Glaukos (GKOS), Luminex (LMNX), Intersect ENT (XENT), ATRION (ATRI), Orthofix (OFIX), Cardiovascular Systems (CSII), K2M Group (KTWO), OraSure Technologies (OSUR) and CryoLife (CRY).

Who are Cerus' key executives?

Cerus' management team includes the folowing people:

Mr. William M. Greenman, Pres, CEO & Director (Age 51)
Dr. Laurence M. Corash, Co-Founder, Chief Scientific Officer, Sr. VP & Corp. Director (Age 74)
Mr. Kevin D. Green, VP of Fin. & CFO (Age 46)
Ms. Chrystal N. Menard, Chief Legal Officer and Gen. Counsel (Age 47)
Dr. Richard J. Benjamin, Chief Medical Officer (Age 58)

Has Cerus been receiving favorable news coverage?

Media coverage about CERS stock has trended somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cerus earned a news impact score of 0.20 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 48.03 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are Cerus' major shareholders?

Cerus' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.27%), Elk Creek Partners LLC (5.41%), Senvest Management LLC (3.11%), Millennium Management LLC (1.33%), Northern Trust Corp (1.12%) and Bamco Inc. NY (0.72%). Company insiders that own Cerus stock include Carol Moore, Chrystal Menard, Kevin Dennis Green, Laurence M Corash, Richard J Benjamin and William Mariner Greenman. View Institutional Ownership Trends for Cerus.

Which institutional investors are selling Cerus stock?

CERS stock was sold by a variety of institutional investors in the last quarter, including Bamco Inc. NY, A.R.T. Advisors LLC, BB&T Securities LLC and Millrace Asset Group Inc.. Company insiders that have sold Cerus company stock in the last year include Carol Moore, Chrystal Menard, Kevin Dennis Green, Richard J Benjamin and William Mariner Greenman. View Insider Buying and Selling for Cerus.

Which institutional investors are buying Cerus stock?

CERS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Senvest Management LLC, Millennium Management LLC, Elk Creek Partners LLC, JPMorgan Chase & Co., Northern Trust Corp, Schwab Charles Investment Management Inc. and Alambic Investment Management L.P.. View Insider Buying and Selling for Cerus.

How do I buy shares of Cerus?

Shares of CERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cerus' stock price today?

One share of CERS stock can currently be purchased for approximately $6.49.

How big of a company is Cerus?

Cerus has a market capitalization of $847.23 million and generates $43.57 million in revenue each year. The biotechnology company earns $-60,580,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Cerus employs 215 workers across the globe.

How can I contact Cerus?

Cerus' mailing address is 2550 STANWELL DRIVE, CONCORD CA, 94520. The biotechnology company can be reached via phone at 925-288-6000 or via email at [email protected]

MarketBeat Community Rating for Cerus (CERS)

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		390 (Vote Outperform)
Underperform Votes:		225 (Vote Underperform)
Total Votes:		615

MarketBeat's community ratings are surveys of what our community members think about Cerus and other stocks. Vote "Outperform" if you believe CERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Cerus (NASDAQ:CERS) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

4 Wall Street analysts have issued ratings and price targets for Cerus in the last 12 months. Their average twelve-month price target is $5.25, suggesting that the stock has a possible downside of 19.11%. The high price target for CERS is $6.00 and the low price target for CERS is $5.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.75	2.75	2.80	3.00
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$5.25	$5.25	$6.20	$7.00
Price Target Upside:	19.11% downside	7.80% upside	23.75% upside	131.79% upside

Cerus (NASDAQ:CERS) Consensus Price Target History

Price Target History for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/9/2018	BTIG Research	Reiterated Rating	Hold		High
1/23/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$5.00	High
12/1/2017	Robert W. Baird	Reiterated Rating	Buy	$5.00	Low
10/5/2017	Cowen	Set Price Target	Buy	$6.00	N/A
3/8/2017	FBR & Co	Set Price Target	Buy	$10.00	Low

(Data available from 5/27/2016 forward)

Cerus (NASDAQ:CERS) Earnings History and Estimates Chart

Earnings by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ:CERS) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.45 EPS
Next Year EPS Consensus Estimate: $-0.38 EPS

Cerus (NASDAQ CERS) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2018
5/8/2018	Q1	($0.12)	($0.11)	$12.22 million	$13.56 million	View	N/A
3/8/2018	Q4 2017	($0.11)	($0.10)	$17.53 million	$16.20 million	View	Listen
11/2/2017	Q3 2017	($0.15)	($0.12)	$11.95 million	$10.80 million	View	N/A
8/3/2017	Q2 2017	($0.16)	($0.16)	$9.14 million	$9.53 million	View	Listen
5/4/2017	Q1 2017	($0.1650)	($0.18)	$8.98 million	$7.01 million	View	Listen
3/7/2017	Q4 2016	($0.16)	($0.13)	$11.29 million	$10.10 million	View	Listen
11/3/2016	Q316	($0.17)	($0.14)	$10.34 million	$10.20 million	View	N/A
8/4/2016	Q216	($0.17)	($0.18)	$8.88 million	$9.25 million	View	N/A
5/3/2016	Q1	($0.16)	($0.17)	$8.29 million	$7.60 million	View	N/A
3/8/2016	Q415	($0.16)	($0.15)	$9.72 million	$9.70 million	View	Listen
11/5/2015	Q315	($0.16)	($0.17)	$10.00 million	$8.04 million	View	N/A
8/6/2015	Q215	($0.15)	($0.17)	$8.71 million	$8.83 million	View	N/A
5/5/2015	Q214	($0.16)	($0.21)	$7.70 million	$7.70 million	View	N/A
2/26/2015	Q114	($0.15)	($0.25)	$10.36 million	$9.70 million	View	N/A
11/4/2014	Q413	($0.13)	($0.15)	$9.83 million	$10.36 million	View	N/A
7/31/2014	Q313	($0.13)	($0.16)	$8.17 million	$8.60 million	View	N/A
5/1/2014	Q313	($0.09)	($0.04)	$9.65 million	$7.86 million	View	N/A
2/25/2014	Q213	($0.09)	($0.10)	$11.77 million	$9.23 million	View	N/A
10/29/2013		($0.09)	($0.29)	$10.34 million	$10.54 million	View	N/A
7/30/2013	Q2 2013	($0.09)	($0.10)	$10.45 million	$10.15 million	View	N/A
4/30/2013	Q1 2013	($0.08)	($0.11)	$9.96 million	$9.73 million	View	N/A
2/28/2013	Q4 2012	($0.08)	($0.11)			View	N/A
11/7/2012	Q3 2012	($0.08)	($0.10)			View	N/A
8/2/2012	Q2 2012	($0.08)	($0.17)			View	N/A
5/1/2012	Q1 2012	($0.08)	($0.08)			View	N/A
2/28/2012	Q4 2011	($0.08)	($0.09)			View	N/A
11/1/2011	Q3 2011	($0.10)	($0.06)			View	N/A
7/28/2011	Q2 2011	($0.10)	($0.13)			View	N/A
4/28/2011	Q1 2011	($0.09)	($0.11)			View	N/A
3/3/2011	Q4 2010	($0.07)	($0.05)			View	N/A
10/28/2010	Q3 2010	($0.09)	($0.10)			View	N/A
7/29/2010	Q2 2010	($0.11)	($0.14)			View	N/A
4/29/2010	Q1 2010	($0.10)	($0.13)			View	N/A
2/23/2010	Q4 2009	($0.12)	($0.13)			View	N/A
10/29/2009	Q3 2009	($0.12)	($0.16)			View	N/A
7/30/2009	Q2 2009	($0.16)	($0.19)			View	N/A
4/30/2009	Q1 2009	($0.18)	($0.21)			View	N/A
2/26/2009	Q4 2008	($0.24)	($0.20)			View	N/A
10/30/2008	Q3 2008	($0.27)	($0.27)			View	N/A
7/31/2008	Q2 2008	($0.26)	($0.28)			View	N/A
5/1/2008	Q1 2008	($0.26)	($0.16)			View	N/A
2/21/2008	Q4 2007	($0.25)	($0.32)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Cerus (NASDAQ:CERS) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Cerus (NASDAQ CERS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.80%
Institutional Ownership Percentage: 60.14%

Insider Trading History for Cerus (NASDAQ:CERS)

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Cerus (NASDAQ CERS) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/17/2018	Kevin Dennis Green	CFO	Sell	73,000	$6.42	$468,660.00	83,825
5/11/2018	Carol Moore	SVP	Sell	60,841	$6.26	$380,864.66	60,841
5/11/2018	Richard J. Benjamin	Insider	Sell	8,631	$6.69	$57,741.39
3/15/2018	Laurence M Corash	Insider	Buy	150,011	$5.15	$772,556.65	1,462,580
3/13/2018	Carol Moore	SVP	Sell	2,623	$5.05	$13,246.15
3/12/2018	Chrystal Menard	insider	Sell	1,960	$4.80	$9,408.00	4,832
3/12/2018	Kevin Dennis Green	CFO	Sell	2,063	$4.80	$9,902.40	58,062
3/12/2018	William Mariner Greenman	CEO	Sell	7,735	$4.80	$37,128.00
8/11/2017	Laurence M Corash	Insider	Buy	92,796	$2.45	$227,350.20	1,375,711
3/15/2017	Kevin Dennis Green	CFO	Sell	2,343	$4.21	$9,864.03
3/15/2017	William Mariner Greenman	Insider	Sell	8,786	$4.21	$36,989.06
3/14/2017	Carol Moore	SVP	Sell	2,377	$4.15	$9,864.55
3/14/2017	Richard J Benjamin	Insider	Sell	1,189	$4.15	$4,934.35	3,000
8/22/2016	Kevin Dennis Green	CFO	Sell	17,150	$6.80	$116,620.00
8/19/2015	Laurence M Corash	Insider	Buy	25,900	$4.99	$129,241.00	1,270,256
8/18/2015	Laurence M Corash	Insider	Buy	84,600	$4.77	$403,542.00
11/10/2014	William Mariner Greenman	CEO	Buy	21,800	$3.93	$85,674.00
11/19/2012	William Mariner Greenman	CEO	Buy	3,200	$3.02	$9,664.00
11/16/2012	Laurence M Corash	Insider	Buy	2,000	$2.85	$5,700.00
11/16/2012	William Mariner Greenman	CEO	Buy	13,800	$2.85	$39,330.00

(Data available from 1/1/2013 forward)

Cerus (NASDAQ CERS) News Headlines

Source:

Date	Headline
	Cerus Co. (CERS) Receives Consensus Rating of "Buy" from Brokerages www.americanbankingnews.com - May 24 at 10:54 AM
	Research Analysts Set Expectations for Cerus Co.'s FY2018 Earnings (CERS) www.americanbankingnews.com - May 24 at 8:38 AM
	Insider Selling: Cerus Co. (CERS) CFO Sells 73,000 Shares of Stock www.americanbankingnews.com - May 18 at 7:55 PM
	Cerus nabs $15M government contract seekingalpha.com - May 17 at 6:04 PM
	Cerus (CERS) Reports Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red ... www.streetinsider.com - May 17 at 8:36 AM
	Cerus Announces Additional BARDA Funding to Support Development of INTERCEPT Blood System for Red Blood Cells finance.yahoo.com - May 16 at 5:25 PM
	New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC ... globenewswire.com - May 15 at 8:46 AM
	New Research Coverage Highlights Cerus, Health Insurance Innovations, Tetra Tech, Ferro, Dril-Quip, and MSC Industrial Direct — Consolidated Revenues, Company Growth, and Expectations for 2018 finance.yahoo.com - May 15 at 8:46 AM
	Richard J. Benjamin Sells 8,631 Shares of Cerus Co. (CERS) Stock www.americanbankingnews.com - May 14 at 10:12 PM
	Insider Selling: Cerus Co. (CERS) SVP Sells 60,841 Shares of Stock www.americanbankingnews.com - May 14 at 10:12 PM
	Zacks Investment Research Lowers Cerus (CERS) to Sell www.americanbankingnews.com - May 14 at 8:10 PM
	Cerus Endovascular Promotes Stephen Griffin, PhD, to President www.prnewswire.com - May 11 at 8:48 AM
	Cerus' (CERS) Hold Rating Reaffirmed at BTIG Research www.americanbankingnews.com - May 10 at 9:08 AM
	Edited Transcript of CERS earnings conference call or presentation 8-May-18 8:15pm GMT finance.yahoo.com - May 9 at 5:21 PM
	Here's Why Cerus Corporation Stock Is Surging Today finance.yahoo.com - May 9 at 5:21 PM
	Here's Why Cerus Corporation Stock Is Surging Today www.fool.com - May 9 at 2:52 PM
	Cerus' (CERS) CEO Obi Greenman on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 8:33 AM
	BRIEF-Cerus Corp Reports Q1 Loss Per Share $0.11 www.reuters.com - May 9 at 8:33 AM
	Cerus: 1Q Earnings Snapshot finance.yahoo.com - May 9 at 8:33 AM
	Cerus (CERS) Issues Quarterly Earnings Results www.americanbankingnews.com - May 8 at 10:30 PM
	Cerus Corporation Reports First Quarter 2018 Results finance.yahoo.com - May 8 at 5:25 PM
	Cerus (CERS) Upgraded at ValuEngine www.americanbankingnews.com - May 5 at 2:27 PM
	Cerus to Present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday May 9, 2018 finance.yahoo.com - May 3 at 5:13 PM
	Cerus (CERS) to Release Quarterly Earnings on Tuesday www.americanbankingnews.com - May 1 at 11:26 AM
	Cerus Co. (CERS) Given Average Rating of "Buy" by Brokerages www.americanbankingnews.com - April 29 at 9:20 AM
	Cerus (CERS) Cut to "Buy" at BidaskClub www.americanbankingnews.com - April 28 at 8:34 AM
	BRIEF-Cerus Announces Health Canada Approval Of The Intercept Blood System For Platelets www.reuters.com - April 25 at 5:20 PM
	Cerus to Release First Quarter 2018 Results on May 8, 2018 finance.yahoo.com - April 25 at 5:20 PM
	Cerus Announces Health Canada Approval of the INTERCEPT Blood System for Platelets finance.yahoo.com - April 25 at 5:20 PM
	Two trendy condo projects aim to provide urban living at cheaper price tag www.bizjournals.com - April 23 at 5:04 PM
	Reviewing Cerus (CERS) and Nevro (NVRO) www.americanbankingnews.com - April 20 at 3:13 AM
	Cerus (CERS) Lowered to "Hold" at Zacks Investment Research www.americanbankingnews.com - April 13 at 7:13 PM
	Cerus (CERS) Lifted to "Hold" at BidaskClub www.americanbankingnews.com - April 12 at 6:47 PM
	Zacks Investment Research Upgrades Cerus (CERS) to "Buy" www.americanbankingnews.com - April 10 at 1:42 PM
	Cerus (CERS) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - April 4 at 8:32 PM
	Cerus Co. (CERS) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - April 4 at 9:32 AM
	Cerus (CERS) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 3 at 8:45 PM
	BRIEF-Cerus' Redes Phase 3 Red Blood Cell Study Expands Into The Continental US www.reuters.com - April 2 at 8:57 AM
	Cerus (CERS) Announces RedeS Phase 3 Red Blood Cell Study Expands Into Continental US www.streetinsider.com - April 2 at 8:57 AM
	Cerus' RedeS Phase 3 Red Blood Cell Study Expands Into the Continental US www.businesswire.com - April 2 at 8:57 AM
	Cerus’ RedeS Phase 3 Red Blood Cell Study Expands Into the Continental U.S. finance.yahoo.com - April 2 at 8:57 AM
	Blood transfusion company inks deal for new East Bay headquarters finance.yahoo.com - March 28 at 5:09 PM
	Cerus (CERS) Given Buy Rating at Cantor Fitzgerald www.americanbankingnews.com - March 26 at 6:30 PM
	Cerus (CERS) Stock Rating Upgraded by BidaskClub www.americanbankingnews.com - March 24 at 1:11 PM
	Cerus Corporation, Shares Up 39% in the Past Month, Analysts Review, INTERCEPT finance.yahoo.com - March 22 at 8:42 AM
	Cerus (CERS) Looks Good: Stock Adds 9.5% in Session - Nasdaq www.nasdaq.com - March 20 at 8:44 AM
	Cerus (CERS) Upgraded to "Strong-Buy" at BidaskClub www.americanbankingnews.com - March 17 at 6:44 PM
	Wired News – FDA Accepted Tyme’s IND Application to Begin Phase-II Clinical Study for SM-88 in Pancreatic Cancer finance.yahoo.com - March 16 at 8:34 AM
	Insider Buying: Cerus Co. (CERS) Insider Buys 150,011 Shares of Stock www.americanbankingnews.com - March 15 at 7:46 PM
	Is Cerus Corporation’s (NASDAQ:CERS) Balance Sheet A Threat To Its Future? finance.yahoo.com - March 15 at 8:30 AM

Cerus (NASDAQ:CERS) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Cerus (NASDAQ:CERS) Income Statement, Balance Sheet and Cash Flow Statement

Cerus (NASDAQ CERS) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff